Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.

1992 • 3,751 citations

A Cell Culture Model for T Lymphocyte Clonal Anergy

1990 • 1,894 citations

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

1992 • 1,608 citations

Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens

1994 • 1,185 citations

Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo.

1996 • 800 citations

T cell defined tumor antigens

1997 • 641 citations

The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro.

1994 • 607 citations

Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells

1997 • 596 citations

Dendritic cells in the T‐cell areas of lymphoid organs

1997 • 572 citations

Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells.

1989 • 542 citations

Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation?

1995 • 347 citations

The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.

1991 • 306 citations

Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.

1983 • 251 citations

Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells.

1992 • 214 citations

Immune regulation: a critical link between NK cells and CTLs

1996 • 164 citations

Effective Tumor Vaccine Generated by Fusion of Hepatoma Cells with Activated B Cells

1994 • 154 citations

Distinct Costimulatory Molecules Are Required for the Induction of Effector and Memory Cytotoxic T Lymphocytes

1997 • 137 citations

Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.

1996 • 128 citations

A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state.

1997 • 127 citations

Mouse tumor rejection antigens P815A and P815B : Two epitopes carried by a single peptide

1992 • 99 citations

Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors

1996 • 99 citations

Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.

1996 • 88 citations

Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity.

1995 • 78 citations

Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.

1995 • 76 citations

IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.

1996 • 65 citations

Processing and presentation of insulin. I. Analysis of immunogenic peptides and processing requirements for insulin A loop-specific T cells.

1987 • 46 citations

Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815

1995 • 46 citations

B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes.

1997 • 38 citations

CD8⁺ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum⁻ or helper peptides in priming for skin test reactivity to a P815AB‐related peptide

1995 • 32 citations

Immune surveillance: Both CD3⁺ CD4⁺ and CD3⁺ CD8⁺ T cells control in vivo growth of P815 mastocytoma

1990 • 16 citations

CULTURE OF DENDRITIC CELLS FROM MURINE BONE MARROW SUPPLEMENTED WITH GM-CSF AND TNF-ALPHA

1994 • 14 citations